# Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

> **NCT02771730** · PHASE1 · TERMINATED · sponsor: **Emergent BioSolutions** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteer
- HIV Vaccine

## Interventions

- **BIOLOGICAL:** Ad4-mgag
- **BIOLOGICAL:** Ad4-EnvC150
- **OTHER:** Placebo Comparator
- **BIOLOGICAL:** AIDSVAX B/E

## Key facts

- **NCT ID:** NCT02771730
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study endpoints not met.
- **Last updated:** 2024-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771730, "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02771730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*